Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases
Introduction: Rapid development and production of vaccines against emerging diseases requires well established, validated, robust technologies to allow industrial scale production and accelerated licensure of products. Areas covered: A versatile Vero cell platform has been developed and utilized to...
Saved in:
Main Authors: | P. Noel Barrett (Author), Sara J. Terpening (Author), Doris Snow (Author), Ronald R. Cobb (Author), Otfried Kistner (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2017-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Seroprevalence study of Toscana virus and viruses belonging to the Sandfly fever Naples antigenic complex in central and southern Italy
by: Serena Marchi, et al.
Published: (2017) -
Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children
by: Pornthep Chanthavanich, et al.
Published: (2018) -
Effects of Statin Combinations on Zika Virus Infection in Vero Cells
by: Erica Españo, et al.
Published: (2022) -
Suscetibilidade da linhagem de células Vero a cepas vacinais do vírus do sarampo Susceptibility of Vero cell line to vaccine strains of the measles virus
by: Célia Sayoko Takata, et al.
Published: (1994) -
Inactivation and Recovery of High Quality RNA From Positive SARS-CoV-2 Rapid Antigen Tests Suitable for Whole Virus Genome Sequencing
by: Guerrino Macori, et al.
Published: (2022)